Acquisition / mergerFiled on BSE ·
Anupam Rasayan completes acquisition of 48.2% stake in Bliss GVS Pharma
Anupam Rasayan · Chemicals & Petrochemicals
What the filing says
- Acquisition finalized on September 28, 2026, at ₹299 per share via Mates Visa Consultancy
- Transaction funded by ₹300 crore term loan plus ₹1,450 crore from Bain Capital-led investors
- Combined platform pro-forma revenue exceeds ₹4,000 crore including Tanfac, Jayhawk, and Bliss GVS
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue: Rank 1Margin: Rank 1
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Anupam Rasayan
- Acquisition / mergerAnupam Rasayan India acquires 2.12% stake in Bliss GVS Pharma on Sept 28, 2026
- Board / shareholder meeting outcomeAnupam Rasayan India Ltd approves 23rd AGM, dividend record date, share acquisition
- Fundraise / allotmentAnupam Rasayan India Ltd acquires 2,60,065 shares in Tanfac Industries Limited
Other acquisition / merger filings this fortnight
- Acquisition / mergerTPL Plastech LtdTPL Plastech Limited to merge with Time Technoplast Limited; share exchange ratio approved
- Acquisition / mergerTPL Plastech LtdTPL Plastech Limited approves merger with Time Technoplast Limited
- Acquisition / mergerNiyogin Fintech LtdNiyogin Fintech schedules meetings for Scheme of Arrangement on Oct 30, 2026
- Acquisition / mergerVasa DenticityVasa Denticity Ltd cancels proposed 31.08% acquisition in IDS Denmed Pvt Ltd
- Acquisition / mergerKronox Lab Sciences LtdKronox Lab Sciences Ltd: Completion of 64.26% share transfer and promoter change
- Acquisition / mergerKronox Lab Sciences LtdKronox Lab Sciences Ltd announces share sale, director resignations, and appointments
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.